Healthy Skepticism Library
Items published during the years 1990 to 1999
There are 2362 items in the Healthy Skepticism Library that were published during the years 1990 to 1999.
Page 9 of 24 pages ‹ First < 7 8 9 10 11 > Last ›
HSL6688
Conlan MF.
In-your-face pharmacy: will the boom in Rx ads aimed at consumers continue?
Drug Topics 1996 Jul; 140:92-94, 97-98
HSL6680
Direct-to-consumer advertising of prescription pharmaceuticals: a Merck Frosst position paper on how to use comprehensive patient information to deliver improved, cost-effective health outcomes
: Merck Frosst 1996 Jun 17
www.hc-sc.gc.ca/hpb-dgps/therapeut/zfiles/english/consult/wkshd2ca.zip
HSL595
Shaughnessy AF, Slawson DC.
Pharmaceutical representatives.
BMJ 1996 Jun 15; 312:(7045):1494
http://www.bmj.com/cgi/content/full/312/7045/1494
HSL9146
Bloor K, Freemantle N.
Lessons from international experience in controlling pharmaceutical expenditure II: Influencing doctors
British Medical Journal 1996 Jun 15; 312:1525-1527
http://www.bmj.com/cgi/content/full/312/7045/1525
HSL6679
Green Shield Canada
Re: direct-to-consumer prescription drug advertising (DTCA)
: Green Shield Canada 1996 Jun 10
www.hc-sc.gc.ca/hpb-dgps/therapeut/zfiles/english/consult/wkshd2ca.zip
HSL601
Robb N.
Sale of prescribing data by pharmacists causes growing concern among physicians.
CMAJ 1996 Jun 1; 154:(11):1747-9
HSL1867
Kelly MH, Murray TS.
Motivation of general practitioners attending postgraduate education.
Br J Gen Pract 1996 Jun; 46:(407):353-6
HSL6665
Health Action International
Drug policy at the 49th World Health Assembly
Amsterdam: Health Action International 1996 Jun
www.haiweb.org
HSL6672
Drug advertising: is this good medicine?
Consumer Reports 1996 Jun; 62-63
HSL6673
Canadian Drug Manufacturers Association
Direct-to-consumer advertising of prescription medications
Toronto, Ontario: Canadian Drug Manufacturers Association 1996 Jun
www.hc-sc.gc.ca/hpb-dgps/therapeut/zfiles/english/consult/wkshd2ca.zip
HSL6674
Canadian Public Health Association
Submission to consensus conference on direct-to-consumer advertising of prescription drugs
: Canadian Public Health Association 1996 Jun
www.hc-sc.gc.ca/hpb-dgps/therapeut/zfiles/english/consult/wkshd2ca.zip
HSL6675
Canadian Society of Hospital Pharmacists
Response to questions to be addressed by the Drugs Directorate consultation workshop on direct-to-consumer advertising (DTCA) of prescription drugs
: Canadian Society of Hospital Pharmacists 1996 Jun
www.hc-sc.gc.ca/hpb-dgps/therapeut/zfiles/english/consult/wkshd2ca.zip
HSL6676
Critser G.
Oh, how happy we will be: pills, paradise, and the profits of the drug companies
Harper’s 1996 Jun39-48
HSL6677
Lexchin J, Vitry A.
Re: the promotion of flagyl (metronidazole)
1996 Jun;
HSL6678
Knowledge is the best medicine: Ontario and PEI partner with PMAC to educate consumers on proper use of medicine
PMAC News 1996 Jun-Jul; 5-6
HSL8344
Amar D.
Radical reform hits France's health care system
Pharmaceutical Executive 1996 Jun; 16:34-36
HSL8345
Drug advertising: is this good medicine?
Consum Rep 1996 Jun; 61:(6):62-3
HSL6671
Consultation workshop: background paper. Direct-to-consumer advertising of prescription drugs
: Drugs Programme 1996 May 28
www.hc-sc.gc.ca/hpb-dgps/therapeut/zfiles/english/consult/wkshd2ca.zip
HSL585
Vitry A, Mansfield P.
Promotion of Coversyl by Servier.
Lancet 1996 May 18; 347:(9012):1411
HSL6670
Canadian Pharmaceutical Association
Re: Drugs directorate consultation workshop on direct-to-consumer prescription drug advertising
: Canadian Pharmaceutical Association 1996 May 16
www.hc-sc.gc.ca/hpb-dgps/therapeut/zfiles/english/consult/wkshd2ca.zip
HSL6669
Pharmaceutical Advertising Advisory Board
Position paper on direct-to-consumer (DTC) prescription drug promotional materials
: Pharmaceutical Advertising Advisory Board 1996 May 15
www.hc-sc.gc.ca/hpb-dgps/therapeut/zfiles/english/consult/wkshd2ca.zip
HSL6667
The Migraine Foundation
Position paper on direct to consumer advertising of prescription medications
: The Migraine Foundation 1996 May 10
www.hc-sc.gc.ca/hpb-dgps/therapeut/zfiles/english/consult/wkshd2ca.zip
HSL6668
Morrice D
1996 May 10
http://www.hc-sc.gc.ca/hpb-dgps/therapeut/zfiles/english/consult/wkshd2ca.zip
HSL9158
Mahaney LM.
Implications of multitier pricing.
Am J Health Syst Pharm 1996 May 1; 53:(9):1002,
HSL6661
Consultation workshop to examine direct-to-consumer advertising
PMAC News 1996 May; 12-14
HSL6662
Towards a better informed consumer of prescription medicines
Ottawa: Pharmaceutical Manufacturers Association of Canada 1996 May
www.hc-sc.gc.ca/hpb-dgps/therapeut/zfiles/english/consult/wkshd2ca.zip
HSL6663
Position paper on direct to consumer prescription drug advertising
: Canadian Medical Association 1996 May
www.hc-sc.gc.ca/hpb-dgps/therapeut/zfiles/english/consult/wkshd2ca.zip
HSL6664
Consumers’ Association of Canada
Protecting the consumer interest in direct-to-consumer advertising of prescription drugs
: Consumers’ Association of Canada 1996 May
www.hc-sc.gc.ca/hpb-dgps/therapeut/zfiles/english/consult/wkshd2ca.zip
HSL6666
Lexchin J, Vitry A.
Re: the promotion of Multiload Cu 375
1996 May;
HSL8920
Wechsler J.
Tug-of-war with FDA
Pharmaceutical Executive 1996 May; 16:18, 20, 22
HSL8921
Vivian JC.
False claims of pharmacist support enjoined in OTC H2 advertising war
Michigan Pharmacist 1996 May; 34:33-34
HSL9142
Wechsler J.
Washington report: SUPAC vs MedGuide: FDA ups and downs
Pharmaceutical Technology Europe 1996 May; 8:16, 18, 20
HSL620
Huston P, Moher D.
Redundancy, disaggregation, and the integrity of medical research.
Lancet 1996 Apr 13; 347:(9007):1024-6
HSL15301
Armstrong D, Reyburn H, Jones R.
A study of general practitioners' reasons for changing their prescribing behaviour.
BMJ 1996 Apr 13; 312:(7036):949-52
http://www.bmj.com/cgi/content/full/312/7036/949?view=long&pmid=8616310
HSL639
Anderson GM, Lexchin J.
Strategies for improving prescribing practice.
CMAJ 1996 Apr 1; 154:(7):1013-7
http://www.cma.ca/cmaj/vol-154/1013e.htm
HSL9174
Cohen MR, Anderson RW, Attilio RM, Green L, Muller RJ, Pruemer JM.
Preventing medication errors in cancer chemotherapy.
Am J Health Syst Pharm 1996 Apr 1; 53:(7):737-46
HSL636
Caudill TS, Johnson MS, Rich EC, McKinney WP.
Physicians, pharmaceutical sales representatives, and the cost of prescribing.
Arch Fam Med 1996 Apr; 5:(4):201-
HSL6659
Lexchin J, Vitry A.
Re: the promotion of Smecta (smectite)
1996 Apr;
HSL6660
This month . . . regulation of prescription drug promotion in Australia
MaLAM Australian News 1996 Apr-May; 4:(4-5):1-8
HSL8347
Leifer C, McCann P.
Medicaid rebates: taming the 800-pound gorilla
Pharmaceutical Executive 1996 Apr; 16:76-78, 80
HSL9160
Carlson AM, Morris LS.
Coprescription of terfenadine and erythromycin or ketaconazole: an assessment of potential harm.
J Am Pharm Assoc (Wash) 1996 Apr; NS36:(4):263-9
HSL642
Alliot LS.
Criticism of Servier re perindopril.
Lancet 1996 Mar 23; 347:(9004):832
HSL593
Soltan HC.
Violence sells.
CMAJ 1996 Mar 15; 154:(6):756,
HSL635
Cho MK, Bero LA.
The quality of drug studies published in symposium proceedings.
Ann Intern Med 1996 Mar 1; 124:(5):485-9
HSL623
Hemminki E, Herxheimer A.
Should drug information be an integral part of health care?
J R Coll Physicians Lond 1996 Mar-Apr; 30:(2):104-6
HSL6654
This month . . . the results of MaLAM’s questionnaire to our subscribers
MaLAM Australian News 1996 Mar; 4:(3):1-5
HSL6655
Clothier R.
MaLAM and pharmaceutical promotion
The Network’s Newsletter 1996 Mar; 5:(1):16
HSL6656
Lexchin J, Vitry A.
Re: the promotion of Lincocin (lincomycin) and Dalacin C (clindamycin)
1996 Mar;
HSL8916
Glaser M.
Chains far outrun independents in advertising OTCs, Rxs
Drug Topics 1996 Mar; 140:14s, 16s
HSL8918
Helwick C.
Are Rx-to-OTC switches fending off generic attacks?
Drug Topics 1996 Mar; 140:30s, 32s
HSL8919
Breu J.
Sustained-release formulations: way out of patent expirations?
Drug Topics 1996 Mar; 140:25s
HSL20386
Robertson N, Baker R, Hearnshaw H
Changing the clinical behaviour of doctors: a psychological framework
Qual Health Care. 1996 Mar; 5:(1):51–54
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1055354/
HSL16728
Wolfe S, Zieve A
Don't Weaken the FDA Laws
The Washington Post 1996 Feb 28
HSL599
Rosenberg SA.
Secrecy in medical research.
N Engl J Med 1996 Feb 8; 334:(6):392-4
HSL6630
Blumenthal D, Causino N, Campbell E, Louis KS.
Relationships between academic institutions and industry in the life sciences--an industry survey.
N Engl J Med 1996 Feb 8; 334:(6):368-73
http://content.nejm.org/cgi/content/abstract/334/6/368
HSL9157
Reilly MJ.
Financial responsibility for adverse reactions
American Journal of Health System Pharmacy 1996 Feb 1; 53:250
HSL603
Peppin JF.
Pharmaceutical sales representatives and physicians: ethical considerations of a relationship.
J Med Philos 1996 Feb; 21:(1):83-99
HSL6632
Boerkamp EJ, Haaijer-Ruskamp FM, Reuyl JC, Versluis A.
The use of drug information sources by physicians: development of a data-generating methodology.
Soc Sci Med 1996 Feb; 42:(3):379-88
http://www.sciencedirect.com/science?_ob=ArticleURL&_udi=B6VBF-3VWPKN3-29&_coverDate=02%2F29%2F1996&_alid=501643267&_rdoc=1&_fmt=&_orig=search&_qd=1&_cdi=5925&_sort=d&view=c&_acct=C000050221&_version=1&_urlVersion=0&_userid=10&md5=1d21858b13b71b2a228e33ad94f0c0f6
HSL6650
Manitoba becomes second province to partner with PMAC knowledge campaign
PMAC News 1996 Feb; 1-2
HSL6651
Sanofi Winthrop claims that Plaquenil “can help prevent the long-term damage of RA” and has a “low incidence of side effects”
MaLAM Australian News 1996 Feb; 4:(2):1
HSL6652
Lexchin J, Vitry A.
Re: the promotion of Arcalion (sulbutiamine) and Duxaril (almitrine/raubasine)
1996 Feb;
HSL6653
Potts R, Vitry A.
Re: the promotion of Plaquenil (hydroxychloroquine)
1996 Feb;
HSL9149
Basara LR.
Weighing direct-to-consumer ads
Pharmaceutical Executive 1996 Feb; 16:68-70
HSL627
Frankel DH.
Servier criticised in perindopril campaign
Lancet 1996 Jan 20; 347:183
HSL3694
Michols D.
The distinction between advertising and other activities.
1996 Jan 12
http://www.hc-sc.gc.ca/hpfb-dgpsa/tpd-dpt/advsactv_e.pdf
HSL9183
Armstrong EP, Langley PC.
Disease management programs.
Am J Health Syst Pharm 1996 Jan 1; 53:(1):53-8
HSL640
Anastasio GD, Little JM Jr.
Pharmaceutical marketing: implications for medical residency training.
Pharmacotherapy 1996 Jan-Feb; 16:(1):103-7
HSL2337
Spingarn RW, Berlin JA, Strom BL.
When pharmaceutical manufacturers' employees present grand rounds, what do residents remember?
Acad Med 1996 Jan; 71:(1):86-8
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=8540971&query_hl=61
HSL6646
The revised IFPMA code
MaLAM International News 1996 Jan; 14:(1):1-2
HSL6648
Lexchin J.
Re: the promotion of Ponstan (mefenamic acid)
1996 Jan;
HSL6649
Vitry A.
Re: the promotion of Coversyl (perindopril)
MaLAM Australian News 1996 Jan;
HSL9140
Keane J.
Thrifty Payless: coming together by staying apart
Wholesale Drugs Magazine 1996 Jan; 48:90, 92, 94
HSL9143
Wechsler J.
Washington report: drug wars: battles over generics and prices
Pharmaceutical Technology 1996 Jan; 20:16, 18, 20, 22, 26, 28, 30, 32
HSL5405
Edwards SS, Vinicky JK, Orlowski JP.
Conflicts of interest, conflicting interests, and interesting conflicts, part 2.
J Clin Ethics 1996 Spr 01; 7:(1):69-76
HSL5406
Orlowski JP, Vinicky JK, Edwards SS.
Conflicts of interest, conflicting interests, and interesting conflicts, Part 3.
J Clin Ethics 1996 Sum 01; 7:(2):184-6
HSL586
Vitry A.
Pharmaceutical promotion: drug advertising affects your prescribing
Australian Prescriber 1996; 19:103
HSL587
Van DER, S , Whyte SR, Hardon A.
The anthropology of pharmaceuticals: a bibliographical approach
Annual Review of Anthropology 1996; 25:155-178
HSL588
Tritsmans L, Briscoe P, Lemmens P, Bussche GV.
Pharmaceutical company trials and the integrity of medical research.
Lancet 1996;
HSL591
Sullivan P.
CMA calls for controls on prescription-drug advertising aimed at patients
Can Med Assoc J 1996; 154:1889-1990
HSL594
Shear NH, Black F, Lexchin J.
Examining the physician-detailer interaction
Can J Clin Pharmacol 1996; 3:(4):175-179
HSL598
Roth MS.
Patterns in direct-to-consumer prescription drug print advertising and their public policy implications.
Journal of Public Policy & Marketing 1996; 15:(1):63-75
HSL600
Rogers A.
Drug companies can broadcast across Europe
Lancet 1996; 347:534
HSL604
Neumann PJ, Zinner DE, Paltiel AD.
The FDA and regulation of cost-effectiveness claims.
Health Aff (Millwood) 1996 Fal; 15:(3):54-71
HSL606
McLaren S.
Cause and effect: prescription drug advertising goes under the microscope
Can Pharm JCan Pharm JCan Pharm J 1996; 129:(5):26-30
HSL609
Lexchin J.
Direct to consumer advertising of prescription drugs: the next steps
Can J Clin Pharmacol 1996; 3:(2):65
HSL610
Lewis S.
Selling guidelines door to door.
CMAJ 1996; 154:756
http://www.cma.ca/cmaj/vol-154/0755e.htm
HSL614
Kopp SW.
Direct-to-consumer advertising and consumer prescription prices
Drug Information Journal 1996; 30:59-65
HSL615
Kondro W.
Canada’s pharmacists can sell prescribing data
Lancet 1996; 347:1401
HSL616
Kondro W.
Canadian doctors’ prescribing habits for sale
Lancet 1996; 347:963
HSL618
Joseph P.
Consumer product information affects us all: iv. medical practitioner view
Australian Prescriber 1996; 19:33-34
HSL619
Jewesson P, Herar S.
Activities of pharmaceutical industry representatives at a major teaching hospital.
Can J Hosp Pharm 1996; 49:256-260
HSL624
Gutkin C, Handfield-jones R.
Guidelines for CME need revamping
Can Fam Physician 1996; 42:1296-1297
HSL625
Greenwald M.
Marketing physician prescribing data
Ontario Medical Review 1996; 63:(10):18
HSL626
Gilbert D, Chetley A.
New trends in drug promotion
Consumer Policy Review 1996; 63:(5):162-167
HSL629
Fogg S.
Consumer product information affects us all: ii. consumer view
Australian Prescriber 1996; 19:32
HSL630
Fisher S.
Hanky-panky in the pharmaceutical industry
International Journal of Psychopathology, Psychopharmacology and Psychotherapy 1996; 1:(1):
HSL631
Dowden JS.
Consumer product information affects us all
Australian Prescriber 1996; 19:30-1
HSL634
Clear PR.
Consumer product information affects us all: i. industry view
Australian Prescriber 1996; 19:31-2
http://www.australianprescriber.com/magazine/19/2/30/4/
HSL641
Amonkar MM, Lively BT.
Pharmacists' attitudes toward product-specific television advertising of prescription drugs
J Pharm Mark Manage 1996; 11:(2):3-20
HSL643
Aldir RE, Jarjoura D, Phinney M, Poordad F, Gutierrez R, Marnejon T, Greifenstein E, Lappin J, Whittier FC.
Practicing and resident physician’s views on pharmaceutical companies.
J Contin Educ Health Prof 1996; 16:25-32
Page 9 of 24 pages ‹ First < 7 8 9 10 11 > Last ›
